OmniAb, Inc. (OABI): Shareholders' Equity

Annual figures by period end, from SEC filings.

$267.03M
As of 2025-12-31
$260.27M
As of 2026-06-30
-7.9%
3-year compound annual growth
$341.37M2021-12-31: $234.31M2022-12-31: $341.37M2023-12-31: $314.58M2024-12-31: $287.62M2025-12-31: $267.03M$267.03M
2021-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$267.03M-7.2%2026-03-04, Balance as of period end
2024-12-31$287.62M-8.6%2026-03-04, Balance as of period end
2023-12-31$314.58M-7.8%2025-03-18, Balance as of period end
2022-12-31$341.37M+45.7%2024-03-25, Balance as of period end
2021-12-31$234.31Mn/a2023-03-30, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
OmniAb, Inc. (OABI)2025-12-31$267.03M-7.2%
Foxo Technologies Inc. (FOXO)2025-12-31$11.14M+109.3%
MaxCyte, Inc. (MXCT)2025-12-31$171.49M-16.9%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$7.28M+179.7%
Absci Corp (ABSI)2025-12-31$189.45M+5.8%
NRC Health (NRC)2025-12-31$13.99M-55.3%
iSpecimen Inc. (ISPC)2025-12-31$3.09M-6.7%
OneMedNet Corp (ONMD)2025-12-31-$2.96Mn/m
Cannabis Bioscience International Holdings, Inc. (CBIH)2025-05-31-$1.16Mn/m

Compare OABI, FOXO, MXCT, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗